{"id":5645,"date":"2024-06-13T16:32:04","date_gmt":"2024-06-13T16:32:04","guid":{"rendered":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/?p=5645"},"modified":"2024-06-14T01:08:13","modified_gmt":"2024-06-14T01:08:13","slug":"frost","status":"publish","type":"post","link":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/2024\/06\/13\/frost\/","title":{"rendered":"Simon Frost"},"content":{"rendered":"<p><img decoding=\"async\" class=\"lazyload alignnone size-full wp-image-5646\" src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png\" data-orig-src=\"http:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png\" alt=\"\" width=\"300\" height=\"300\" srcset=\"data:image\/svg+xml,%3Csvg%20xmlns%3D%27http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg%27%20width%3D%27300%27%20height%3D%27300%27%20viewBox%3D%270%200%20300%20300%27%3E%3Crect%20width%3D%27300%27%20height%3D%27300%27%20fill-opacity%3D%220%22%2F%3E%3C%2Fsvg%3E\" data-srcset=\"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost-66x66.png 66w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost-150x150.png 150w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost-200x200.png 200w, https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-content\/uploads\/sites\/91\/2024\/06\/Simon-Frost.png 300w\" data-sizes=\"auto\" data-orig-sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p>Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes.\u00a0 In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies.\u00a0 Simon now serves on the boards of several organizations, including RARE-X, Global Genes, Uncommon Cures, the Cures Acceleration Network Review Board at the NIH, Cure AHC, Hope For Annabel, and the Genomic Answers for Children\u2019s Health Alliance.\u00a0\u00a0 Simon earned bachelor&#8217;s and master&#8217;s degrees in economics from Cambridge University and a bachelor&#8217;s degree in finance from the University of South Africa.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simon Frost is the CEO of Tiber Capital Group, an investment company that operates large portfolios of single-family homes.\u00a0 In 2017 his daughter Annabel was diagnosed with an ultra-rare neurological disease, Alternating Hemiplegia of Childhood, and since then he has dedicated much of his time to advancements in rare disease research and therapies.\u00a0 Simon now [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5646,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":["post-5645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-creative"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/comments?post=5645"}],"version-history":[{"count":1,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5645\/revisions"}],"predecessor-version":[{"id":5647,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/posts\/5645\/revisions\/5647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media\/5646"}],"wp:attachment":[{"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/media?parent=5645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/categories?post=5645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.roseliassociates.com\/ninds-genetic-strategies\/wp-json\/wp\/v2\/tags?post=5645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}